[Form 4] CLOROX CO /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Linda J. Rendle, Chief Executive Officer and Director of The Clorox Company (CLX), reported an award of 34,281 shares of Common Stock on 09/16/2025 at a reported price of $124.85 per share, increasing her beneficial ownership to 167,537 shares. The filing indicates these shares are Restricted Stock Units that will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.

Insights

Corporate Governance Expert

TL;DR: CEO received restricted stock units increasing insider ownership; vesting schedule spreads compensation over four years.

The Form 4 documents a grant of 34,281 common shares to Linda J. Rendle, reported as Restricted Stock Units vesting in four equal annual installments beginning October 5, 2026. From a governance perspective, multi-year vesting aligns executive incentives with longer-term shareholder outcomes and preserves retention over the vesting period. The report shows total beneficial ownership of 167,537 shares after the grant. The disclosure is routine and directly reflects a compensation award rather than an open-market transaction.

Securities Analyst

TL;DR: Insiders increased reported ownership via RSU grant; transaction is a compensatory issuance, not a market purchase or sale.

This Form 4 records an award of 34,281 Common Stock at a reported price of $124.85, which appears as a compensatory grant (Restricted Stock Units) with a clearly stated vesting schedule. The filing updates beneficial ownership to 167,537 shares. The filing was executed by an attorney-in-fact on 09/18/2025. There is no indication of open-market trading or disposition in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Rendle Linda J

(Last) (First) (Middle)

1221 BROADWAY

(Street)

OAKLAND CA 94612-1888

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOROX CO /DE/ [ CLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		A(1)		34,281	A	$124.85	167,537	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units will vest in 4 equal installments - 1/4 on each of October 5, 2026, 2027, 2028, and 2029.

	By Jinho Joo, Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Linda J. Rendle report on the CLX Form 4?

She reported an award of 34,281 Common Stock on 09/16/2025, recorded as Restricted Stock Units.

How many shares does Linda Rendle beneficially own after the transaction?

The filing reports 167,537 shares of Common Stock beneficially owned following the reported transaction.

What is the vesting schedule for the Restricted Stock Units reported on the Form 4?

The RSUs vest in four equal installments: one-quarter on each of October 5, 2026, 2027, 2028, and 2029.

What price is reported on the Form 4 for the awarded shares?

The reported price is $124.85 per share for the 34,281 Common Stock units on 09/16/2025.

Who signed the Form 4 and when was it signed?

The form was signed by Jinho Joo, Attorney-in-Fact, on 09/18/2025.